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ABSTRACT 
This meta-analytic review evaluated the effectiveness of depression interventions on the 
psychological and immunological outcomes of people living with HIV in sub-Saharan Africa. 
14 studies, yielding 932 participants were eligible. A random-effects models indicated that 
depression interventions were followed by large reductions in depression scores (effect size 
= 1.86, 95% CI = 1.71, 2.01, p < 0.01). No significant effect on immune outcome was 
observed, however there was a trend toward immune improvement of medium effect size 
(effect size on CD4 count and/or viral suppression = 0.57, 95% CI = -0.06, 1.20, p = 0.08). 
Pharmacological interventions appeared to have a significantly larger improvement in 
depression scores than psychological interventions. The greatest improvement in immune 
status was demonstrated in psychological treatments which incorporated a component to 
enhance HIV medication adherence, however these results did not reach significance. Small 
sample sizes and highly heterogeneous analysis necessitate caution in interpretation. The 
results of this meta-analysis should thus be treated as preliminary evidence and used to 
encourage further studies of immunopsychiatry in HIV in sub-Saharan Africa.  
Keywords 
CD4; depression; HIV/AIDS; immunopsychiatry; intervention; meta-analysis; 
psychoneuroimmunology; review; sub-Saharan Africa; viral load 
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1. INTRODUCTION 
Sub-Saharan Africa is the centre of the HIV epidemic, with nearly 26 million people (69% of 
the global burden) estimated to be infected [1]. Improved access to antiretroviral therapy 
(ART) [1] is associated with the 34% increase in life expectancy in sub-Saharan Africa over 
the past 15 years [2]. However, the change in prognosis has revealed vast challenges of this 
chronic disease endemic in resource limited populations. Major depressive disorder (MDD) 
is the most common psychiatric manifestation associated with HIV infection [3], and one of 
such challenges. It is twice as common in people living with HIV as in general populations [4, 
5], with a prevalence of up to 36% [6-8], and a treatment gap estimated to be as high as 90% 
in low and middle income countries[9].  
The primary aim of this systematic review and meta-analysis was to evaluate the 
effectiveness of depression interventions on the psychological and immunological outcomes 
of people living with HIV in sub-Saharan Africa. The secondary aim was to assess which 
types of interventions appear to have the largest effect on depression and immunological 
outcomes.  
1.1 Aetiology of Major Depressive Disorder in People living with HIV 
Psychological, social and biological factors are all implicated in the aetiology of MDD in 
HIV[10]. Psychosocial risk factors identified in the sub-Saharan African population include: 
female gender, older age, unemployment, negative life events, childhood trauma, disability 
and impaired function, poor social support, low quality of life, life-time attempted suicide, 
and associated psychiatric illness [10, 11].  
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The biological aetiology of MDD in people living with HIV is linked, at least in part, to the 
pro-inflammatory cascade driven by the HIV infection [12, 13]. Rivera-Rivera et al 
demonstrated a broad panel of pro-inflammatory cytokines in the plasma of individuals with 
HIV and depression symptoms compared to their non-depressed counterparts [14]. In 
animal models, a single exposure to HIV Tat-protein in the mouse brain induces brain 
cytokines signalling of IL-1β, TNF-α, and IL-6, which culminates in depressive-like behaviour 
[15].  Similarly, elevated levels of IL-1β, IL-6, and TNF-α have been identified in both the 
plasma and cerebrospinal fluid of depressed patients [16]. The rise in these cytokine levels 
are thought to induce the sickness behaviour which manifests as depression in people with 
HIV [13]. 
1.2 The Effect of Major Depressive Disorder on Immunity 
The biological pathways of MDD itself can contribute to low immunity, and increased 
mortality in people living with HIV [17]. For example, MDD and distress states associated 
with MDD, influence the regulation of stress hormones, such as cortisol and catecholamines, 
decreasing pro-inflammatory (anti-viral) immunity [18] while increasing anti-inflammatory 
immunity [19]. This can lead to alterations in the function and/or number of lymphocytes 
and natural killer (NK) cells [18, 20-22], and enhance HIV replication [23]. As a result, dual 
diagnosis patients with HIV and MDD may have increased rates of progression to advanced 
stages of disease [13, 24, 25].  
Furthermore, symptoms of MDD such as impaired concentration, memory, problem-solving 
and motivation [26] can result in negative HIV related behaviours. Most notable of these, is 
a delay in initiating [27], and impairment in adhering to, ART [28, 29]. However, poor mental 
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health predicts faster HIV disease progression even after controlling for adherence [30] and 
is independently associated with increased HIV mortality [17, 30, 31].  
1.3 Management of Major Depressive Disorder in People Living with HIV 
The cornerstone of MDD management in people living with HIV is psychopharmacologic 
treatment using antidepressants [32]. Selective serotonin reuptake inhibitors (SSRI) are first-
line due to their efficacy and minimal adverse effects [33]. SSRI treatment may have a 
direct immunomodulatory effect [34] [35, 36], since serotonin (5-hydroxytryptamine [5-HT]) 
receptors and the 5-HT transporter are found on monocytes, macrophages, T cells, and 
possibly NK cells [37]. By downregulation of HIV receptor and co-receptor expression on 
these immune cells, treatment with SSRI may reduce susceptibility to cellular infection [34] 
[38].  
In contrast, psychological modalities for treatment are recommended as the first-line 
intervention by the WHO’s Mental Health Gap Action Programme (mhGAP) [39]. In a global 
review by Sherr et al, of 90 interventional studies for depression in people living with HIV, 
psychological interventions were assessed to be generally more effective than 
pharmacological treatments [40] in reducing depression.  Furthermore, evidence suggests 
that psychological interventions for people living with HIV may improve immune status by 
modulating the associated neuroendocrine pathways [20]. Animal and human studies have 
demonstrated that stress accelerates HIV-1 disease pathogenesis and impairs the biological 
impact of ARV treatment [41].  
In summary, multiple pharmacological and psychological interventions for depression have 
been evaluated for people living with HIV, with some studies also assessing the impact of 
treatment on immune measures. However, to date the majority of reviews of depression 
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studies for people living with HIV have reported on the population of white males, from the 
United States (US) or Europe [40]. There has not been a systematic review and meta-
analysis examining which treatment modalities result in the most significant improvements 
in both depression and immune status in the sub-Saharan Africa population, where most 
HIV patients are.  
2. METHODS 
2.1 Data Sources  
Relevant studies were identified by searching the electronic databases: MEDLINE, EMBASE, 
PsycINFO, and The Cochrane Library. All searches were conducted on 27 July 2016 and no 
limits were applied. The search terms (Appendix 2) reflected four categories: (1) HIV/AIDS, 
(2) Depression, (3) Intervention, and (4) Sub-Saharan Africa. Experts and authors in the field 
of depression in people living with HIV in sub-Saharan Africa were contacted and asked to 
respond with any missing literature. A hand search of reference sections from relevant 
articles was conducted and ‘grey literature’, including conference abstracts, was explored 
using OpenGrey and WorldCat databases. A repeat search was performed in Pubmed on 5 
March 2018 with no relevant new studies found. 
2.2 Study Selection 
Published and unpublished studies (in any language) were included in the systematic review 
if they met all 4 of the following criteria: (1) described an intervention aimed at reducing 
depression in people living with HIV, (2) targeted individuals 18 years of age or older, (3) set 
in Sub-Saharan Africa and (4) reported outcome data on pre- and post-intervention 
depression outcomes as a score rating, with or without immunological data. Studies 
included in the meta-analysis, additionally, required that the mean and standard deviation 
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of pre- and post-intervention total outcomes, or sufficient information to calculate this, was 
available.  
Participant populations with a specified comorbidity (e.g. drug abuse) as well as perinatal 
studies, were excluded since this would introduce external physical factors. As this analysis 
compares change scores within groups, both ART treated and ART naïve patients were 
included. Research studying the initiation of ARTs was excluded due to expected significant 
immune status improvement.  
2.3 Data Extraction 
Studies from the electronic databases, grey literature and hand searching were exported 
into reference manager, EndNote [42], where duplicates were removed. Study title, abstract 
and text screening was performed, repeated by a second author (IE), and discrepancies 
reconciled via discussion. From the selected studies, information was extracted using 
standardised abstraction table.  
2.4 Quality Assessment 
The Cochrane Collaboration’s Tool for Assessing Risk of Bias [43] was used to assess level of 
quality and corresponding levels of bias in each study. This tool assesses methodologic 
quality variables of random sequence generation, allocation concealment, blinding of 
participants, personnel and outcomes, incomplete outcome data, selective reporting and 
other bias. 
2.5 Analytic Approach  
2.5.1 Outcome Variables 
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We found that most studies had used more than one instrument to measure immunological 
and/or depression outcomes (see Table 1 and Table 2). To reduce the measurement 
variance and optimize the comparison of outcomes, we chose to analyse the instruments 
used most frequently across studies. For depression outcomes, these were the Beck 
Depression Inventory-II, Patient Health Questionairre-9, Self-Reporting Questionnaire-8, and 
the Hamilton Depression Scale. For immunological outcomes, these were CD4 count and 
viral suppression. Due to the large variation in intervention time frame and follow up, we 
analysed the first time point as the outcome, compared to the baseline measure.  
2.5.2 Effect Size Calculation 
In two separate analyses, the mean immunological and depression outcomes pre- and post-
intervention were used to calculate a change-from-baseline effect size (ES) also known as 
the Standardized Mean Difference (Cohen’s d [44]) (Appendix 3). Only the ‘change scores’ 
from the interventional arm were analysed. For this, a version of the Cohen’s d calculation 
known as the Standardised Mean Gain (SMG) was used to calculate ES. The ‘change score’ 
approach is recommended when participants are not all randomised (Higgins et al., 2011) or 
for studies with small sample sizes, which are susceptible to baseline imbalances [45]. The 
method is well suited for this review, as a comparison of outcomes could be made without 
the need for a control group to be present in every study.  
The ES for depression outcomes were calculated from continuous variables (depression 
score), while immunological outcomes were both dichotomous (viral suppression) and 
continuous (CD4 count). Immune outcomes were first analysed in separate outcomes of CD4 
and viral suppression, before being combined into a unified immune outcome.  The ES of 
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dichotomous data from viral suppression was converted to continuous data (see calculation 
in Appendix 3) to allow for combination with CD4 count change scores. 
The corrected effect size was calculated using Hedge’s g to produce an unbiased [46] final 
result. By convention, a positive sign is assigned to the effect size when there is 
improvement from pre- to post-intervention (i.e. the bigger the change from baseline, the 
better the outcome). A negative sign is assigned when the effect is in the opposite direction. 
2.5.3 Cochrane Collaboration Review Manager 5 
Data calculated was then entered into Cochrane Collaboration Review Manager 5 [47] for 
meta-analysis. A weighted effect size for each study is generated (i.e. inverse variance) using 
Hedges formula [48] based on the standard error (SE) of each ES. The I2 statistic was chosen 
to calculate the degree of statistical heterogeneity because of the small number of studies 
[49]. Since heterogeneity was high between studies, a random effects model was used. This 
generates a conservative estimate of variance providing more generality [50]. 
2.5.4 Stratified Analysis 
Stratified analyses of depression and immune outcomes was performed to examine 
whether intervention characteristics moderated the strength of the aggregated effect size. 
Once the most common treatment groups were identified, we compared the aggregated 
effect sizes. The subgroups between-group heterogeneity was calculated using the I
2
 
statistic and the test for subgroup differences was done using the Chi2 statistic. 
Due to the large variation in intervention types, wide-ranging treatment subgroups had to 
be identified. A comparison of pharmacological vs non-pharmacological was the broadest, 
and most logical, subgroup category. Delivery methods, ARV status, treatment location and 
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duration, and antidepressant drug groups were considered for stratified analysis, but not 
conducted, due to lack of information on these factors, or wide varieties (e.g. five different 
antidepressants), making a comparison number within subgroups too small to assess. 
3 RESULTS 
3.1 Study and Sample Characteristics  
As shown in the PRISMA Flow Diagram (Appendix 1), 14 articles were deemed eligible for 
review. Of these, 13 studies had sufficient information to be included in the meta-analysis 
for depression outcomes and five for immunological outcomes, totalling 932 participants. 
Data abstraction (Table 3) showed studies took place from 2006-2016 in Sub-Saharan 
African countries, namely South Africa, Nigeria, Uganda, Tanzania, Zimbabwe, and 
Cameroon, with the majority in South Africa (43%). Majority of interventions were set in HIV 
clinics or HIV day clinics within a hospital (57%). The largest study sample size was 184 
participants [51] and the smallest was 9 [52]. The majority of participants were female (73%) 
with age range of 21-56 years. Most studies (57%) included only patients known to be on 
ART. The remaining studies included mixed ART and non-ART patient samples or did not 
specify the ART status. Three studies (21%) had patients  
known with poor adherence at baseline.  
3.2 Intervention Characteristics and Components  
Study designs were: 36% randomised control trials, 14% non-randomised control trials, and 
50% interventional trials without a control arm. Half of the studies used a pharmacological 
approach. Both selective serotonin reuptake inhibitors (Escitalopram, Citalopram, 
Fluoxetine) and tricyclic antidepressants (Amitriptyline and Imipramine) were prescribed. 
One study (Moosa et al, 2012) compared and independently reported results from a 
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pharmacological and non-pharmacological intervention within the same study. Results from 
both arms of this study were analysed separately in the stratified analysis, to avoid over-
representation. The components of psychological interventions varied extensively. Problem-
solving therapy and cognitive behavioural therapy were most commonly used psychological 
interventions (28%). Psycho-education, interpersonal therapy, and art psychotherapy were 
used for the remaining interventions. Task-shifting was the most common delivery approach 
(57%) across all interventions. In this model, tasks normally performed by a physician are 
transferred to a health professional with a different or lower level of education and training, 
or to a person specifically trained to perform a limited task only without having formal 
health education [53]. The remaining studies (43%) used medical officers, a stepped-care 
model, or did not specify. All pharmacological treatment was received as a daily dose. The 
median number of non-pharmacological intervention sessions was 6 (range: 1–8 sessions). 
The median intervention duration was 12 weeks (range: 4 – 24 weeks).  
3.3 Methodologic Quality of Studies  
Random sequencing, allocation concealment and blinding was lacking or unclear in over 
75% of studies. From the six studies with the highest levels of bias, majority (four) were 
pharmacological interventions [51, 54-56] and two were non-pharmacological studies [57, 
58]. Attrition bias was low (21%), with most studies having small dropout rates, and giving 
clear explanations thereof. Reporting bias was also low, as 100% of studies state clearly the 
aim and outcomes being examined. With majority of studies being non-RCT trials (64%), the 
lack of random assignment and a placebo control groups, results in a generalized poor level 
of quality.   
3.4 Effect Size Analysis of Depression & Immune Outcomes 
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3.4.1 Depression Outcomes 
Analysis of depression outcomes revealed a large aggregated ES reflecting the magnitude of 
change from pre- to post-intervention and providing strong evidence for post-intervention 
improvement in depression (SMG = 1.86, 95% CI = 1.71, 2.01; p <0.0001). Two studies 
contribute to the majority of the weight of the analysis: Peltzer et al, 2012 and Ngo et al, 
2015 (Figure 1).  
 
Figure 1:  Forest Plot Depression Outcome Change Scores  
3.4.2 Immune Outcomes 
Three out of the four studies reporting CD4 count, showed an improvement post-
intervention (Figure 2.1). However only one showed a significant ES [59].  The one study 
eliciting a negative effect on CD4 outcome had a non-significant result [60]. The overall 
effect was in the direction of favouring post-treatment improvement in CD4 count, but the 
ES was small (SMG = 0.15, 95% CI = -0.15, 0.44, p = 0.33) and failed to reach statistical 
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significance. 
Figure 2.1: Forest Plot Immune Outcome Change Scores (CD4 Count) 
Results from the three studies using viral suppression as an outcome, indicate that the odds 
of being virally suppressed are four times greater post-treatment of depression. However, 
the final effect, although favouring post-intervention with a medium ES, had wide 
confidence intervals and just failed to reach statistical significance. (OR = 4.00, 95% CI 
=0.82,19.49, p = 0.09) (Figure 2.2). 
Figure 2.2: Forest Plot Immune Outcome Change Scores (Viral Suppression) 
Combining of immune outcome CD4 count and viral suppression, showed post-intervention 
immune improvement (Figure 2.3). This analysis provides a narrow 95% CI (-0.06; 1.20), but 
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the final result just crosses the line of no effect, showing a medium effect size (SMG = 0.57), 
and trend-level statistical significance (p = 0.08).  
Figure 2.3: Forest Plot Immune Outcome Change Scores (Combined CD4 Count and Viral 
Suppression) 
Between study heterogeneity accounted for over 90% of variance in the ES of both 
depression and immune outcomes, indicating that, although favouring the same direction of 
effect, diversity between studies is extremely high reflecting the combined construct 
measures.  
3.5 Stratified Analysis 
3.5.1 Non-Pharmacological verse Pharmacological Interventions 
3.5.1.1 Depression Outcomes 
Although both pharmacological and non-pharmacological treatments show significant 
improvement in depression outcomes post-intervention, the ES of pharmacological 
treatments is more than double the ES of non-pharmacological treatments. Thus, there was 
a large and significant subgroup difference (Chi2 = 10.21, df = 1, p < 0.01) favouring 
pharmacological intervention improvement in depression scores (Figure 3.1).   
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Figure 3.1 : Forest Plot Depression Outcomes : Non-Pharmacological Vs Pharmacological Interventions 
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3.5.1.2 Immune Outcomes  
Neither pharmacological nor non-pharmacological interventions show significant immune 
effects independently. The pharmacological interventions who reported immune outcomes 
(two studies both using CD4 count outcomes) have, if anything, a negative effect on 
immunity, however, this result shows a minute effect size, with no significance (SMG = -
0.06, 95% CI = -0.29, 0.18, p = 0.64). In contrast, non-pharmacological interventions (three 
studies, two of which used CD4 count outcomes, and one using viral suppression as an 
outcome) show a trend towards immune improvement with a large but non-significant 
effect size (SMG = 1.02, 95% CI = -0.19, 2.24, p = 0.10). The effects of the interventions are 
in opposition, making the resulting subgroup difference between interventions large (Chi2 = 
2.29, df = 1). However, the small comparison yields a non-significant (p = 0.09) result (Figure 
3.2).  
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Figure 3.2 : Forest Plot Immune Outcomes : Non-Pharmacological Vs Pharmacological Interventions 
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4. DISCUSSION 
This study is the first systematic review and meta-analysis of depression interventions for 
people living with HIV in sub-Saharan Africa. It demonstrates improvements in both mental 
health and immune status with varying levels of clinical and statistical significance.  
4.1 Depression Outcomes 
The findings in this study are in keeping with a previous systematic review of depression 
interventions for people living with HIV, in mainly high-income countries [40], with most 
interventions being statistically effective in reducing depression. However, contrary to the 
findings by Sherr et al, which showed psychological interventions to be more effective than 
pharmacological interventions, our study found that antidepressant treatment was more 
effective than psychological interventions in the reduction of depression scores. This could 
suggest that psychotropic treatments for depression could be more effective and offer 
better outcomes in a sub-Saharan Africa population. However, these findings need to be 
confirmed in larger samples or future systematic reviews. 
The variation in treatment response might be explained by ethnic differences between this 
study populations and previous studies with majority European/American populations. For 
example, genetic profile has been shown to predict better antidepressant outcomes in an 
ethnicity-dependent manner [61]; however, another study found no significant differences 
between White and African-American MDD patients in their response to pharmacological 
versus psychological treatments [62]. Of course, the use of Western-developed 
psychological treatments in an African setting could explain the less significant improvement 
in our meta-analysis; indeed, Griner et al suggest that mental health treatments should be 
modified to better match cultural context, with a meta-analysis indicating a moderately 
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strong benefit of culturally adapted interventions on depression outcomes [63]. 
Alternatively, delivering high quality psychological treatments may be difficult in the context 
of sub-Saharan Africa where facilities and trained psychologist are limited. In fact, the 
majority of the studies using psychological treatment in our meta-analysis recruited lay 
health workers to deliver the intervention (6 of 8 studies) whereas a much smaller 
proportion of the pharmacological interventions were delivered by lay health care workers 
(3 out of 7); and psychosocial informational interventions may require more advanced skill 
training in lay health workers to achieve superior outcomes in this resource-constrained 
setting [59]. Furthermore, within our meta-analysis, studies using pharmacological 
interventions had, on average, a longer treatment duration (mean 14 weeks) compared to 
studies using a non-pharmacological intervention (mean 10 weeks). Successful treatment of 
depression, in both pharmacotherapy and psychotherapy treatment, relies heavily on 
provider contact to be effective [64]. Discrepancies in treatment duration is thus a possible 
confounder of these results. Lastly, the majority (5/8) of pharmacological intervention 
studies were assessed to have high levels of selection, performance and/or detection bias, 
thus results should be treated with caution. We can only speculate the reasons for the 
greater success of pharmacological depression treatment in this setting, and further 
research is required to better explain this finding. 
4.2 Immunity Outcomes 
Five studies measured both depression and immune outcomes, but the correlation between 
improvement in depression and immune outcomes was not tested statistically in any of the 
papers.  However, the relationship between improvement in depression and immune 
outcomes was discussed briefly by two individual papers in this review [6, 59]. Gaynes et el 
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emphasized that this finding is consistent with a model in which effective depression care 
yields improved HIV outcomes [6].  
In the meta-analysis, no significant immunological improvements were observed in either 
the psychological or pharmacological treatment arms. This finding is endorsed by a meta-
analysis of cognitive-behavioural interventions, by Crepaz et al, which showed significant 
intervention effects on symptoms of depression (d = 0.33) but limited evidence suggesting 
effects on CD4 cell counts (d = 0.08) [65]. Similarly, two recent, randomized trials of 
medication-based depression treatment in the US showed no effect on HIV outcomes [66, 
67]. In the first study, fluoxetine significantly improved depression but with no statistically 
significant differences in secondary HIV outcomes between intervention and control arm 
[66]. In the second study, the largest trial of its kind among HIV-infected adults, a three-year 
medication based depression treatment did not improve HIV outcomes but achieved 
clinically significant depression improvements. Notably, these results were thought to be 
due to high baseline ART adherence in this study population [67]. 
However, the trend towards immune improvements, particularly demonstrated by 
psychological interventions, in this review are also in keeping with research in the field. Two  
RCTs, one providing cognitive-behavioural stress management [68] and another mindfulness 
meditation training [41], demonstrated an increase in NK cells and CD4+ T-cells (b = 106.27, 
SE = 56.89, t [66] = 1.87, p = .06), together with evidence of a buffered CD4+ T lymphocyte 
decline (b = .014, t (74) = 2.09, p = .04), respectively. International studies, in the US, using 
antidepressant treatment have similarly shown a trend toward improvement in immune 
status. A prospective cohort study in California showed that treatment with antidepressants 
(non-specified) resulted in double the odds of achieving viral suppression (95% CI, 1.15-
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3.58; P = .02), and nearly doubled the odds of achieving complete adherence to ART 
(weighted OR, 1.94; 95% CI, 1.20-3.13; P = .006) [69]. Another cohort study  found that 
among depressed patients, those compliant with SSRI had improved ART adherence and 
statistically greater increases in CD4 cell responses [70].  Furthermore, the CHARTER cohort 
HIV study  reported that individuals taking SSRIs were more likely to have lower HIV viral 
loads in cerebrospinal fluid and better neuropsychological performance [71].  
4.3 Effects of ART Adherence 
It is important to note that the psychological treatments included in the meta-analysis all 
had an adherence component incorporated into the intervention. It is well established that 
depression in people living with HIV is significantly associated with non-adherence to ART 
[72]. A recent South African study demonstrated that patients reporting non-perfect 
adherence were approximately three times more likely to have moderate to severe 
symptoms of depression than those reporting perfect adherence [73]. After treatment for 
depression, a meta-analysis by Sin et al [74] has showed that the odds of a person adhering 
to ART were 83 % better. The resulting immune improvements in depression treatment are 
thus thought to be primarily mediated through the increased ART adherence when being 
treated for depression [70, 75]. Relationships between immunity, depression, and 
adherence appear to be closely intertwined 
The lack of immune improvement seen with primarily psychotropic interventions in this 
review tentatively suggests that treatment modalities relying solely on antidepressants 
might not be addressing the underlying issues associated with non-adherence in lower-
middle income setting of sub-Saharan Africa. Adherence counselling within depression 
management in this research and others discussed above, appears to be a necessary and 
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successful component of treatment, which indirectly improves immune outcomes. In the 
context of sub-Saharan Africa, perhaps this should be considered an essential requirement 
in mental health policy. However, these findings are derived from a very small body of 
evidence and did not reach statistical significance, making evidence preliminary. Whether or 
not non-pharmacological interventions also improve immune outcomes through additional 
brain-body connection mechanisms is difficult to assess in this context, and might be better 
understood if future studies use a homogeneous population of people living with HIV 
already adherent to ART medication. Future research in the field might help further identify 
and promote the most effective methods of improving both mental and physical health for 
this population.  
4.4 Limitations 
In terms of methodological limitations, the studies in this review were generally of low 
quality and small sample size. The limited number of studies necessitated the inclusion of 
non-RCT trials in the meta-analysis, which can compound the biases present and generate 
misleading results [76]. There were insufficient studies to examine the effects of individual 
study characteristics (i.e. moderators and confounders) on the effect sizes. This could 
substantially contribute to better understanding factors underlying the effectiveness of 
different intervention groups. Comparing two different methods of treatment interventions 
can result in high levels of heterogeneity. Although sub-group analysis attempted to group 
similar treatments, there still exists high heterogeneity in sample size, time frame and study 
design, which calls for caution in interpretation since results being compared were very 
different in nature.  
5. CONCLUSION 
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The evidence provided in this paper confirms that depression interventions are effective in 
the treatment of depression for people living with HIV in sub-Saharan Africa. However, the 
most effective treatment modalities for depression in people living with HIV in sub-Saharan 
Africa may differ compared with Western countries. Most notably, pharmacological 
treatment demonstrated a significantly larger improvement in depression score than 
psychological treatment modalities. These findings, however, are derived from a small body 
of poor quality research and should thus be treated as preliminary evidence only.  Weak 
evidence exists for the effects of depression intervention on immune status in this 
population. Future research in sub-Saharan Africa ought to invest in methodologically sound 
RCTs to allow data collected to be meaningfully interpreted. Furthermore, mental health 
research could benefit from a broader collection of physical health outcomes to permit 
better understanding and advances in the field of psychoneuroimmunology. 
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Table 1: Depression Outcomes Measures 
Depression measure Study 
BDI-II Olley 2006; Peltzer et al., 2012; Field & Kruger 2008 
PHQ-9 Abas et al., 2016; Ngo et al., 2015; Petersen et al., 2014; Gaynes et al., 
2015; Wagner et al., 2014; Pence 2014; Adams et al., 2012 
SRQ-8 Abas et al., 2016; Nyamayaro et al., 2016  
HAM-D Hoare et al., 2014; Moosa & Jeenha 2012; 
MADRS Hoare et al., 2014; 
HSCL-25 Petersen et al., 2014 
SCID-I Moosa & Jeenha 2012; 
CESD-R Andersen et al.,  2016 
 
Table 2: Immune Outcome Measures 
Immune measure Study 
CD4 count Peltzer et al., 2012; Ngo et al., 2015; Gaynes et al., 2015; Wagner et al., 
2014; Hoare et al., 2014; Adams et al., 2012; Nyamayaro et al., 2016; 
Pence et al., 2014  
CD8 count Hoare et al., 2014  
HIV RNA viral 
suppression 
Abas et al., 2016; Gaynes et al., 2015; Nyamayaro et al., 2016  
HIV RNA viral load Gaynes et al., 2015; Pence et al., 2014  
 
  
1 
 
 
1 
 
Table 3: Data Abstraction 
Author(s), 
Year, 
Country 
Participants:  
Sample size (N): 
Intervention (I) 
Control (C) 
Gender (M/F) 
Age (SD/range) 
ART Status 
Depression status 
Intervention: 
Study type, intervention, 
control, setting 
Delivery: 
Number of 
sessions, 
duration of 
intervention 
Outcomes 
Measured: 
Depression 
outcomes used in 
review: 
Immunological 
outcomes used in 
review: 
 
Intervention (I) 
 
Control (C) 
Result summary Risk of 
Bias: 
The 
Cochrane 
Collaborati
on’s tool 
for 
assessing 
risk of bias 
Low(L) 
Unclear(U) 
High(H) 
1.  
Peltzer et 
al., 2012 
KwaZulu-
Natal, South 
Africa 
 
 
 
N= 152 
I= 76 
C= 76 
 
M =53 
F =99 
Age = 36.9 SD=9.5 
 
6-24 months on ART 
treatment with 
Randomised control trial 
 
Intervention: Manualised 
cognitive behaviour group 
adherence intervention 
 
Lay health 
worker/adherence 
counsellor led 
 
Sessions = 
3 
(1/month) 
 
Duration of 
intervention 
= 3 months 
Adherence 
 
CD4 count 
 
Beck 
Depression 
Inventory II-total 
out of 63points, 
>20 depression 
 
BDI ANOVA= 0.018 
(p=0.894) 
 
I= baseline 26.8 (SD 
22.2) f/u 19.7 (SD 
19.3) 
Change: -7.1 
 
C= baseline 25.5 
(SD 23) f/u= 19.2 
CD4 count ANOVA= 
0.675 (p=0.412)  
 
I= baseline 308 (SD 
217) 
FU 384 (SD 186) 
Change= 76 
 
C= baseline 264 (SD 
170)  
Both treatment 
and control arms 
show 
improvements in 
immune and 
depression 
outcomes. Better 
immune outcomes 
in control arm. No 
significant 
Selection: 
L/U 
Performance
: U 
Detection: U 
Attrition: L 
Reporting: L 
Other: L 
  
2 
 
 
2 
 
adherence problems 
 
All patients scored 
as depressed on 
baseline BDI but not 
specified as in 
inclusion  criteria 
Control: Treatment as usual 
 
ART Clinic 
Measured at 
baseline, month 
1 and month 4 
 
 
(SD 17.4) 
Change: -6.3 
 
 
F/U= 368 (SD 196)  
Change= +104 
 
 
 
difference 
between 
intervention and 
control conditions.  
 
2.  
Nyamayaro 
et al., 2015 
 
Harare, 
Zimbabwe 
 
 
 
N = 32 
I= 14 
C= 18  
 
M= 11 
F= 21 
Age= 37.8 (24,6-
44.9) 
 
On ART > 6 months 
with risk of poor 
adherence 
 
Mild depression at 
baseline assessed 
by PHQ-9>9 
Two-arm pilot randomised 
controlled trial  
 
Problem-Solving therapy 
combined with Adherence 
counselling using a stepped 
care approach 
 
Lay health 
worker/adherence 
counsellor led 
 
Hospital Family Care 
Centre, government clinic 
Sessions= 6 
 
Duration of 
intervention 
= 8 weeks 
Viral load 
(detectable viral 
load >200 
copies/ml) 
 
Patient Health 
Questionnaire 
for depression  
 
Shona Symptom 
Questionnaire 
for common 
mental disorders  
 
Adherence 
PHQ9 
I: baseline 13.8 (SD 
2.2) F/U 3.1 (SD 3.1)  
Change: 10.8 (95% 
CI 12.9, 8.8) 
 
C: baseline 9.2 (SD 
3.3) F/U 5.7 (SD 3.9) 
Change: 3.4 (95% 
CI 5.8, 1.4) 
 
Intervention change 
(adjusted for 
baseline): 4.7 points 
lower (95% CI -8.2, -
1.3 p=0.010) 
Viral suppression  
I : baseline 7.1% ; F/U: 
75% 
Change : 67.9% 
 
C : baseline 5.6% ; 
F/U 50% 
Change : 44.4% 
 
Data missing from 
(38% of participants) 
Greater 
improvement in  
immune and 
depression 
outcomes in 
treatment arm 
after controlling for 
baseline scores 
Selection: L 
Performance
: H 
Detection: L  
Attrition: L 
Reporting: L 
Other: L 
  
3 
 
 
3 
 
3.  
Hoare et al., 
2014 
 
Stellenbosc
h, South 
Africa 
 
N = 102 
I= 51 
C= 51 
 
M= 12 
F= 90 
 
Age =34 (23-56) 
 
ART: not specified 
 
Major depressive 
disorder at baseline 
assessed DSM-IV 
MINI-international 
neuropsychiatric 
interview-plus  
Fixed-dose, placebo-
controlled, semi-
randomized, double-blind 
(convenience sampling)  
 
Escitalopram 10mg PO OD 
 
Delivery and monitoring not 
specified 
 
Hospital based intervention 
Duration of 
intervention
= 6 weeks 
 
Daily dose 
Montgomery-
Asberg 
depression 
rating scale 
 
Hamilton 
depression 
rating scale 
 
CD4 count 
 
CD8 count 
HAM-D=   
I: baseline 21.3 (SD 
5.2) F/U: 12.3 (SD 
1.0) Change: -9 
 
C: baseline 19.6 (SD 
5.5) F/U: 11.8 (SD 
8.4) 
Change: -8 
 
Treatment 
difference: 
1.1 (SE 1.7) 
(p=0.98) 
 
 
ANCOVA model 
CD4 
I: baseline 454.3 (SD 
29.5) F/U 433.6 (SD 
214.9) 
Change: -10.9 
 
C: baseline 
404.1 (SD 218.5) F/U 
436.8 (SD 210.6)  
Change:43.3 
 
Treatment difference: 
-54.0 (SE 35.6) 
(p=0.2) 
 
Depression scores 
improved 
significantly in 
both intervention 
and control arm, 
however no 
significant 
advantage for 
Escitalopram over 
placebo. Better 
immune 
outcomes in 
control arm and 
worse immune 
outcomes in 
intervention arm 
(nonsignificant) 
 
Selection: L 
Performance
: L  
Detection: U 
Attrition: L 
Reporting: L 
Other: L 
  
4 
 
 
4 
 
4.  
Petersen et 
al., 2014 
 
KwaZulu-
Natal, 
South Africa 
 
  
N= 76 
I= 41 
C= 35 
 
Analysis N= 17 (high 
dropout) 
 
M= 50 
F= 25 
 
Age= (range only)  
2i-59 
 
On ART 
 
Major depressive 
disorder at baseline 
assessed by SRQ-
20 
 
Randomized controlled trial 
 
Group-based IPT 
counselling intervention 
using a task shifting 
approach 
 
Delivered by HIV clinic 
counsellors 
 
HIV clinic  
Duration of 
intervention
= 3 months 
 
Number of 
sessions= 8 
PHQ-9 
 
HSCL-25 
Hopkins 
symptoms check 
list 
PHQ-9 
I: baseline mean 
15.47 (SD 4.46) F/U 
6.94 (SD 4.14) 
ANOVA analysis 
mean difference 
scores of 8.53  
 
C: baseline mean 
15.18 (SD 5.46)  
F/U 11.06 (SD 4.58) 
ANOVA analysis 
difference score of 
4.12 (F(1, 
32)=23.88, p<.0001 
NO 
IMMUNOLOGICAL 
OUTCOME 
Significantly 
greater 
improvement on 
depression scores 
on the PHQ9 in 
the intervention 
Selection: L 
Performance
: L    
Detection: L 
Attrition: H 
Reporting: L 
Other: L 
  
5 
 
 
5 
 
5.  
Moosa and 
Jeenah 
2012 
 
Soweto, 
South Africa 
Total N= 62 
 
Intervention1 = 19 
Intervention 2= 13 
 
Control= 30  
 
M= 15 
F= 75 
 
Age= 36.8 (24-53) 
 
On ARVs  
 
Major depressive 
disorder  assessed 
according to DSM-IV 
criteria 
Randomised control open 
label study 
 
Intervention 1: 
Antidepressant (citalopram) 
20mg 2/52 
Increase by 10-20mg in the 
absence of improvement 
 
 
Intervention 2: 
psychotherapy Inter 
personal therapy (IPT) 
 
Delivery and monitoring not 
specified  
 
Controls:  not depressed 
 
HIV Clinic 
Duration of 
study= 8 
weeks 
 
1: Daily 
dose  
 
2: Number 
of sessions 
of IPT= 5-12 
Structured 
Clinical 
Interview for 
DSM-IV 
Axis I Disorders: 
(SCID-I) and the  
 
Hamilton 
Depression 
Rating Scale 
(HAMD) 
 
HAMD mean score 
I1: Baseline 25.7 
(4.5) F/U 6.2 (4) 
Change: 19.5 
 
I2: baseline 22.5 
(4.5) F/U 8.2 (4) 
Change:14.3 
 
C: Baseline 2.1 (SE 
0.30) (95% LCL 1.5; 
95% UCL 2.7), with 
a range from 0 to 5  
F/U: 1.62 (SE 0.49) 
(95% LCL 0.62; 95% 
UCL 2.62), range 
from 0 to 14.  
Difference: 0.6  
NO 
IMMUNOLOGICAL 
OUTCOME 
 
Improvements in 
depression 
outcome in both 
the IPT and 
antidepressant 
arm, with greater 
improvement 
observed in 
antidepressant 
arm. 
No comment can 
be made 
regarding 
comparison to 
control arm, since 
this is a different 
population (not 
depressed)  
Selection: H 
Performance
: H  
Detection: U 
Attrition: U 
Reporting: L  
Other: U 
  
6 
 
 
6 
 
6.  
Gaynes et 
al., 2015 
 
Bamednda, 
Cameroon 
 
 
 
I= 41 
 
M=10   
F=31  
 
Age 39.1 (29, 51) 
 
On ART (analysis 
done only 
participants with 3 
months of treatment) 
 
Major depression 
disorder 
PHQ9> 10 
(moderate 
depressive severity) 
 
Pilot interventional cohort 
 
Depression care manager 
 
 
Measurement-Based Care 
Antidepressant 
(amitriptyline) prescription, 
follow up and management 
of side effects 
 
Delivered by non-physician 
 
 
Sessions = 
6 
 
Duration of 
intervention
=3 months 
 
PHQ9 
 
CD4 count 
 
Viral load (log) 
 
Virologic 
suppression (< 
400 copies/mL) 
 
Adherence 
 
HIV symptoms 
decrease 
Alcohol use 
 
Risky sexual 
behaviour 
PHQ9  
Baseline score= 
14.4 (13.1, 15.6) 
F/U: 1.6 (0.8, 2.4) 
 
Mean difference: -
12.8 (-14, -11.3) 
 
Remission (PHQ-9 < 
5) = 36 (90%) 
CD4 count   
Baseline 436 (2, 860) 
F/U: 452 (32, 876) 
Mean Difference (95% 
CI): +16 (-47, 79) 
 
 
Viral suppression (% 
<400 copies/mL) =  
Baseline: 0 
F/U: 5 (18%) 
Mean Difference (95% 
CI):18% (4%, 32%) 
Improved 
depression and 
immunological 
outcomes. 
Significance of 
results not 
clarified.  
 
Selection: H 
Performance
: L 
Detection: H 
Attrition: L 
Reporting: L 
Other: L 
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7.  
Abas et al, 
2016 
 
Harare, 
Zimbabwe 
 
 
 
N= 9 
 
M= 4  
F= 5  
 
Age= 42.1 (35-65) 
 
On ART> 4 months 
 
Known with 
adherence problems 
 
Probable depression 
(SRQ8) 
Open-label pilot trial 
 
Stepped care intervention 
combining problem-solving 
therapy for depression with 
enhanced counselling for 
antiretroviral therapy 
adherence 
 
ART clinic 
 
Delivered by adherence 
counsellors  
Duration of 
intervention
=6 months 
 
Number of 
sessions= 6 
Shona Self 
Report 
Questionnaire 
(SRQ-8) 
 
CD4 count 
 
Viral 
suppression 
 
SRQ-8 mean  
baseline= 5.6 
F/U: 1.8 
Mean difference: 
3.8 
 
CD4 count mean  
baseline= 398.75 
mean follow up= 
470.86 
Mean difference 72,1  
 
Viral load suppression 
baseline= 57.14 
at follow up= 100% 
Mean difference 
42.86% 
Improved 
depression and 
immunological 
outcomes. 
Significance of 
results not 
clarified. 
 
Selection: H 
Performance
: H   
Detection: L 
Attrition: L 
Reporting: L 
Other: L 
8.  
Pence et al., 
2014 
 
Bamenda, 
Camaroon 
 
 
 
N = 55 
 
M= 11  
F= 44  
 
Age = 40 (33–44) 
 
On ART 
 
MDD/PHQ9> 10 
Interventional trial  
 
Measurement-Based Care 
(MBC)  
 
Depression care manager 
(non-physician) 
 
amitriptyline 25–50 mg OD 
 
Duration of 
intervention 
= 12 weeks 
 
Daily dose 
 
Number of 
sessions= 4 
PHQ-9  
 
CD4 count 
baseline 
 
HIV RNA viral 
load (copies/mL) 
 
HIV RNA viral 
load\400 
PHQ-9  
Baseline= 13 (12–
16) 
F/U= 2 (0–3) 
Change 
= -11 
BASELINE 
IMMUNOLOGICAL 
DATA ONLY 
 
CD4 baseline = 454 
(242–612) 
 
Viral load baseline= 
12,304 (7,308–21,555) 
Significant 
improvement in 
depression 
outcomes: 
94 % response to 
treatment.  
Selection: H 
Performance
: H  
Detection: U 
Attrition: L 
Reporting: L 
Other: L 
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(moderate 
depressive severity) 
 
Delivered by nurse/social – 
Worker 
 
Day hospital AIDS treatment 
centre 
 
9.  
Wagner et 
al., 2014 
 
Kampala, 
Uganda 
 
 
N = 105 
 
M= 19  
F= 86  
 
Age= 37 (10) 
Major depression 
 
80% of participants 
on ARVs, all 
medically stable 
Interventional longitudinal 
prospective cohort study 
 
Antidepressant: 93% treated 
with Fluoxetine 20mg OD 
increasing by 20mg 
increments 
17% treated with imipramine 
50 mg increasing to 75mg 
then 2mg increments 
 
Delivery and monitoring not 
specified 
 
HIV clinic 
Duration of 
intervention 
= 6 months 
 
 
Daily dose 
PHQ-9 
 
CD4 count 
baseline only 
 
 PHQ9 mean: 
Baseline= 16.7(SD 
5.2) 
F/U= 1.9 (SD 3.6) 
Mean difference= 
-14.8 
 
BASELINE 
IMMUNOLOGICAL 
DATA ONLY 
 
CD4 count baseline 
=346 (SD 243) 
Significant 
improvement in 
depression 
outcomes: 
86% treatment 
response 
 
 
Selection: H 
Performance
: H  
Detection: H 
Attrition: L 
Reporting: L  
Other: L 
10.  
Ngo et al., 
N= 184 
 
Open label interventional 
drug trial 
Duration of 
intervention
PHQ-9 
 
PHQ9 mean 
Baseline: 14.9 (SD 
BASELINE 
IMMUNOLOGICAL 
Significant 
Improved in  
Selection: H 
Performance
  
9 
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2015 
 
Uganda 
 
 
M=40 
F= 144 
 
Age= 36.4 (9.3) 
 
85.9% of 
participants on ART 
 
Major depressive 
disorder (MINI) 
 
Newly started on 
ART, not on ART, or 
more than 6 months 
on ART (mixed 
group) 
 
fluoxetine (20 mg/day, 
increments of 20 mg as war- 
ranted) or imipramine (50 
mg/day, increased to 75mg 
after two weeks, followed by 
increments of 25 mg as 
warranted)  
 
Treated by psychiatric 
medical officers hired and 
trained by the study 
 
HIV/non-HIV clinics 
= 6 months   
 
Daily dose  
 
F/U= 6 
months 
CD4 count 5.1) 
F/U: 2.6 (SD 3.8) 
DATA ONLY 
 
CD4 mean at 
baseline: 243.6 (SD 
214.7) 
 
 
depression 
outcomes with 
79% treatment 
response 
: H 
Detection: H  
Attrition: L 
Reporting: L 
Other: L 
11.  
Field and 
Kruger, 
2008 
 
Limpopo, 
South Africa 
 
Total N= 18 
 
I= 9 
C=9 
 
M= 0 
F= 18 
 
Non-randomised control trial 
 
Art therapy 
 
Recruitment: HIV support 
group 
 
Delivery and monitoring not 
Duration of 
intervention
= 4 weeks 
 
Number of 
sessions= 1 
Beck 
Depression 
Inventory II-total 
out of 63points, 
>20 depression 
 
CHANCE HLOC 
 
BDI-II mean score  
I= Mean difference=  
-0.529, SD 0.167 
 
C= -0.1376 SD 
0.231  
 
Difference in means: 
NO 
IMMUNOLOGICAL 
OUTCOME 
Significant 
difference in 
depression 
outcomes 
Selection: H 
Performance
: L   
Detection: L 
Attrition: L 
Reporting: L  
Other: H 
(simultaneou
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Age= 29.9 (21-42) 
 
ART status not 
specified 
 
BDI> 14 (Mild-mod 
depression) 
specified 
 
-0.39 
Significance: (t (16)= 
4.11, p<0.05) 
 
s HIV 
support 
group 
sessions) 
12.  
Adams et 
al., 2012 
 
Tanzania 
 
Total N= 20 
 
M= 6  
F= 14 
 
Age= ≥18 (not 
specified further) 
 
ARV status not 
specified 
 
Depression at 
baseline assessed 
by PHQ-9 
Nurse-led antidepressant 
medication management of 
depression 
 
Amitriptyline 
 
(two-week shortage of 
medication) 
 
Duration of 
intervention
= 12 weeks 
 
 
Daily 
medication 
dose 
 
3 follow up 
visits 
PHQ-9 
 
CD4 count 
baseline only 
 
PHQ9 mean and 
SD: 
Baseline= 19.76 
(3.01) 
F/U= 8.12 (1.83) 
 
(t = 19.62, df = 16, p 
< 0.001) 
 
Mean difference= 
11.64 
 
 
NO 
IMMUNOLOGICAL 
OUTCOME 
Significant 
improvement in 
depression 
outcomes 
Selection: H 
Performance
: H    
Detection: H 
Attrition: L 
Reporting: L   
Other: L 
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13.  
Andersen et 
al., 2016 
 
Western 
Cape, South 
Africa 
 
 
N= 14 
 
M= 1 
F= 13 
 
Age= 38.4 (7.81) 
 
 
On ART (time not 
specified) 
 
MDD (MINI) 
psychologist 
diagnosed 
interventional trial 
 
Intervention: Nurse-
delivered CBT for adherence 
and depression 
 
HIV clinic 
Duration of 
intervention
= 2 months 
 
Number of 
sessions= 6- 
8 
 
F/U= 3 
months after 
completion 
(5 months 
after start) 
CES-D 
 
SDS 
 
MINI 
 
Hamilton 
Depression 
Rating Scale 
(HAMD) 
 
HAM-D 
baseline (M = 26.4, 
SD = 5.5)  
F/U: (M = 5.8, SD = 
5.8), with a very 
large 
Effect size (Cohen’s 
d = 2.5) 
Change : (γ = −0.71, 
SE = 0.18, 95% 
CI [−1.15, −0.28], 
t(17) = −3.89, p < 
.01 
NO 
IMMUNOLOGICAL 
OUTCOME 
Significant 
improvement in 
depression 
outcomes with a 
very large 
effect size 
Selection: H 
Performance
: H   
Detection: H 
Attrition: U 
Reporting: L 
Other: L 
14.  
Olley, 2006 
 
Abuja, 
Nigeria 
 
 
N= 62 
 
I= 34 
C= 33 
 
M= 27 (43.5%) 
F= 35 (56.5%) 
 
Age= 27.4 (SD 8.1) 
BDI mean > 14 
Non-randomised control trial 
 
Intervention: Psycho-
education 
 
Control: Waitlist  
 
Voluntary Counselling and 
Testing (VCT) centre 
 
Duration of 
intervention
= 4 weeks 
 
Number of 
sessions= 4 
x 1 hour, 1 
session a 
weekly 
 
Beck 
Depression 
Inventory II-total 
out of 63points, 
>20 depression 
 
The crown crisp 
Experiential 
Index 
 
BDI mean 
I: Baseline= 19.0 
(SD 6.4) 
F/U= 5.71 (1.5) 
 
C: Baseline=17.04 
(SD 1.5) 
F/U= 14.16 (2.5) 
NO 
IMMUNOLOGICAL 
OUTCOME 
Significant 
improvement in 
depression 
outcomes 
intervention 
compared to 
control 
 
Main effect F 
value: 21.06 
Selection: H 
Performance
: U 
Detection: U  
Attrition: L 
Reporting: L  
Other: L 
  
12 
 
 
12 
 
But not inclusion 
criteria 
 
Not on ART, newly 
diagnosed HIV 
 
Delivered by VCT counsellor  
 
F/U= 4 
weeks 
Sexual risk 
behaviour 
 
Self-disclosure 
intentions# 
 
Coping 
behaviours 
P<0.00 
 
  
13 
 
13 
 
Appendix 1: PRISMA Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Records identified through 
database searching  
(n = 962) 
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Additional records identified 
through grey literature search  
(n=163) 
 
Records after duplicates removed 
(n= 678) 
Titles/abstracts of 678 
screened  
Records excluded 
(n= 626) 
51 Full-text articles 
assessed for eligibility  
Full-text articles excluded: 
• Inappropriate 
study type (n = 24) 
• Protocol (n = 1) 
• Full text could not 
be obtained 
(n =  1) 
• Systematic 
reviews (n = 1) 
• Book chapter 
review (n=1) 
• Inappropriate 
population (n= 9) 
• No depression or 
immunological 
outcomes (n= 3) 
 
14 Studies included in 
systematic review  
14 Studies included in 
meta-analysis 
Additional records 
identified through 
bibliographies/hand 
search/contacting 
researchers in the field  
(n = 3) 
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Appendix 2: Search Strategy 
Search Terms: Embase, PsychInfo, Medline 
1. exp HIV/  
2. (HIV or AIDS or (acquired adj2 immunodeficiencey adj2 syndrome)).mp. [mp=ti, ab, hw, tn, 
ot, dm, mf, dv, kw, tc, id, tm, nm, kf, px, rx, ui]  
3. exp HIV Infections/  
4. exp Human immunodeficiency virus/  
5. exp acquired immune deficiency syndrome/  
 
6. OR/1-5 
 
7. exp depression/  
8. depress*.mp.  
9. exp Depressive Disorder, Major/  
10. exp major depression/  
 
11. OR/7-10 
 
12. exp psychoneuroimmunology/  
13. psychoneuroimmunology.mp.  
14. immunopsychiatry.mp.  
15. exp clinical trials/  
16. Experiment controls/  
17. exp Placebo/  
18. exp intervention/  
19. exp psychotherapy/  
20. (intervention or trial or treatment).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tc, id, tm, nm, 
kf, px, rx, ui]  
21. control groups/  
22. exp "clinical trial (topic)"/  
23. exp comparative study/  
24. control groups/ or double-blind method/ or single-blind method/  
25. exp antidepressant agent/  
26. exp intervention studies/  
 
27. OR/12-26 
 
28. (Angola or Benin or Botswana or Burkina Faso or Burundi or Cabo Verde or Cameroon or 
Central African Republic or Chad or Comoros or Congo, Dem Rep or Congo Rep or Cote 
d'Ivoire or Equatorial Guinea or Eritrea or Ethiopia or Gabon or Gambia or Ghana or 
Guinea or Guinea-Bissau or Kenya or Lesotho or Liberia or Madagascar or Malawi or Mali 
or Mauritania or Mauritius or Mozambique or Namibia or Niger or Nigeria or Rwanda or 
(Sao Tome and Principe) or Senegal or Seychelles or Sierra Leone or Somalia or South 
Africa or South Sudan or Sudan or Swaziland or Tanzania or Togo or Uganda or Zambia or 
Zimbabwe).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tc, id, tm, nm, kf, px, rx, ui]  
29. exp "Africa south of the Sahara"/  
30. Sub-Saharan Africa.mp. 
31. remove duplicates from 28-30 
 
32. OR/28-31 
 
6 AND 11 AND 27 AND  32
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Appendix 3: Meta-Analysis Formulae  
Standardized Mean Gain Depression Outcomes 
dCohen	s	d	av: SMG = 					 	!"   
#$% = 	&#$'( + #$*(2  
#,-	. =	&21− 1233 +	4 	5-	.
(
24  
* Corr is the correlation coefficient. No studies included correlation coefficients data, thus a value of 
0.5 was assigned as a reasonable and conservative estimate [77]. 
 
Unstandardized Mean Gain Immunological Outcomes (where constructs are the same) 
Unstandardized	mean	gain = Post	Intervention	mean − Pre	Intervention	mean 
 
 Hedge’s g 
?@5A@	B	A = 12ℎ@4	B5	 × 1 −	 34G − 9 
* N is the total number of participants in the study 
 
Dichotomous Data 
I55B	JKLM24 = 	 Pre	Intervention	event	aN3@	M4L@3O@4LM24	42	@O@4L	P 	÷ 	 N2BL	R4L@3O@4LM24	@O@4LSN2BL	R4L@3O@4LM24	42	@O@4L5 
#,lnIJ = &1K + 1P + 1S + 15	 
 
Approximation of Dichotomous to Continuous Data 
,U@SL	#MV@ = lnIJ . √Y3  
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Appendix 4.1 : Effect Size Calculations: Depression Outcomes 
Study  Pre  
Intervention 
Score Mean 
Pre Intervention 
Score Standard 
Deviation 
Post 
Intervention 
Score Mean 
Post Intervention 
Score Standard 
Deviation 
Number of 
Participants 
Standardized 
Mean Gain 
(Cohen’s d) 
Heges g Standard 
Error Gain 
score 
Abas, 2015 13.8 2.2 3.1 3.1 14 -4.034 -3.93 0.80 
Adams, 2012 19.16 3.01 8.12 1.83 20 -4.81 -4.72 0.77 
Andersen, 2016 40.9 8.45 6.58 7.61 14 -4.27 -4.16 0.85 
Field & Kruger, 
2008 
    9 -3.17 -3.04 0.82 
Gaynes, 2015 14.4 0.825 1.6 0.4 41 -24.98 -24.7 2.70 
Hoare, 2014 21.3 5.2 12.3 1 51 -2.90 -2.88 0.28 
Ngo, 2015 14.9 5.1 2.6 3.8 184 -2.76 -2.76 0.16 
Nyamayaro, 
2016 
5.6 0.5 1.8 1 9 -5.07 -4.86 1.18 
Olley, 2006 19 6.4 5.7 1.5 82 -3.36 -3.35 0.29 
Peltzer, 2012 26.8 22.2 19.7 19.3 76 -0.34 -0.34 0.12 
Pence, 2014 13 1 2 0.75 55 -12.57 -12.49 1.20 
Petersen, 2014 15.47 4.46 6.94 14.4 41 -1.98 -1.97 0.27 
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Wagner, 2014 16.7 5.2 1.9 3.6 105 -3.36 -3.35 0.25 
Moosa, 2012 
(pharm) 
25.7 4.5 6.2 4 19 -4.59 -4.50 0.78 
Moosa, 2012 
(IPT) 
22.5 4.5 14.3 4 13 -1.93 -1.87 0.47 
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Appendix 4.2 : Effect Size Calculation: Immune Outcomes, Odds of Viral Suppression 
Study Pre Intervention Odds Post Intervention Odds Number of Participants Log (Odds Ratio) Standard Error of 
Change 
Abas, 2015 1/13 11/3 14 1.68 1.22 
Gaynes, 2015 0/27 5/22 41 1.13 1.50 
Nyamayaro, 2016 0/9 5/4 9 1.19 1.55 
 
Appendix 4.3: Effect Size Calculation: Immune Outcomes, CD4 Count (Abas, 2015 result converted from dichotomous viral 
suppression (VS) to continuous) 
Study Pre 
Intervention 
Score Mean 
Pre 
Intervention 
Score Standard 
Deviation 
Post 
Intervention 
Score Mean 
Post 
Intervention 
Score Standard 
Deviation 
Number of 
participants 
Standardized 
Mean Gain 
(Cohen’s d) 
Hedges 
g 
Standard 
Error Gain 
Score 
Peltzer, 
2012 
308 217 384 186 76 0.38 0.38 0.11 
Hoare, 2014 454.3 29.5 433.6 214.9 51 -0.17 -0.17 0.14 
Gaynes, 
2015 
436 21405 452 211 41 0.08 0.07 0.16 
Nyamayaro, 
2016 
398.75 157025 470.86 162.5 9 0.46 0.43 0.33 
Abas, 2015 VS VS VS VS 14 2.28 2.21 0.27 
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Highlights 
• Pharmacological interventions appeared to have a significantly larger improvement in depression scores than psychological modalities 
of treatment, in sub-Sahara African studies  
• Psychological treatment interventions, incorporating an HIV medication adherence component, had the most pronounced, however 
non-significant, effect on immune status improvement 
• Antidepressant treatment might not be addressing the underlying issues associated with non-adherence in lower-middle income 
setting of sub-Saharan Africa 
• A tentative recommendation from this preliminary evidence is combination treatment for MDD in people living with HIV, using both 
psychological and pharmacological modalities. However, more evidence of better quality is needed to support future policy in this 
region.  
 
